Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ERNA NASDAQ:GELS NASDAQ:ITRM NASDAQ:TNFA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeERNAErnexa Therapeutics$4.54-16.4%$7.90$3.18▼$71.50$6.33M2.51.37 million shs185,545 shsGELSGelteq$0.61+3.4%$0.62$0.39▼$2.02$6.32M-0.5595,411 shs193,535 shsITRMIterum Therapeutics$0.03$0.03$0.03▼$1.42$1.60M2.964.85 million shsN/ATNFATNF Pharmaceuticals$3.45+0.3%$3.89$0.04▼$8.94$6.37M2.0432.22 million shs88,166 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceERNAErnexa Therapeutics-15.42%-1.99%-12.42%+13.90%-89.03%GELSGelteq-2.69%+9.26%-43.29%-22.35%-67.59%ITRMIterum Therapeutics0.00%0.00%0.00%0.00%-96.73%TNFATNF Pharmaceuticals0.00%-4.71%-14.43%-8.51%-60.69%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeERNAErnexa Therapeutics$4.54-16.4%$7.90$3.18▼$71.50$6.33M2.51.37 million shs185,545 shsGELSGelteq$0.61+3.4%$0.62$0.39▼$2.02$6.32M-0.5595,411 shs193,535 shsITRMIterum Therapeutics$0.03$0.03$0.03▼$1.42$1.60M2.964.85 million shsN/ATNFATNF Pharmaceuticals$3.45+0.3%$3.89$0.04▼$8.94$6.37M2.0432.22 million shs88,166 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceERNAErnexa Therapeutics-15.42%-1.99%-12.42%+13.90%-89.03%GELSGelteq-2.69%+9.26%-43.29%-22.35%-67.59%ITRMIterum Therapeutics0.00%0.00%0.00%0.00%-96.73%TNFATNF Pharmaceuticals0.00%-4.71%-14.43%-8.51%-60.69%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceERNAErnexa Therapeutics 2.00Hold$30.00560.79% UpsideGELSGelteq 1.00SellN/AN/AITRMIterum Therapeutics 1.67ReduceN/AN/ATNFATNF Pharmaceuticals 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest ITRM, TNFA, ERNA, and GELS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026ERNAErnexa Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/26/2026GELSGelteq Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/11/2026GELSGelteq Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/11/2026ERNAErnexa Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/7/2026GELSGelteq Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/7/2026ERNAErnexa Therapeutics Brookline Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$30.004/22/2026GELSGelteq Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026ERNAErnexa Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 7/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookERNAErnexa Therapeutics$580K9.16N/AN/A$7.64 per share0.59GELSGelteq$110K59.38N/AN/A$1.08 per share0.56ITRMIterum Therapeutics$390K4.10N/AN/A($0.15) per share-0.20TNFATNF PharmaceuticalsN/AN/AN/AN/A$286.76 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateERNAErnexa Therapeutics-$14.08M-$26.20N/AN/AN/AN/A-263.74%-151.16%8/12/2026 (Estimated)GELSGelteq-$4.30MN/AN/AN/AN/AN/AN/AN/AN/AITRMIterum Therapeutics-$24.77M-$0.75N/AN/AN/AN/AN/A-65.54%N/ATNFATNF Pharmaceuticals-$23.36M-$231.00N/AN/AN/AN/A-69.21%-33.98%N/ALatest ITRM, TNFA, ERNA, and GELS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2026N/AERNAErnexa Therapeutics-$3.30N/AN/AN/AN/AN/A6/30/2026Q2 2026GELSGelteqN/A-$0.12N/A-$0.12N/AN/A5/20/2026Q1 2026ERNAErnexa Therapeutics-$1.95-$6.95-$5.00-$6.95N/AN/A5/11/2026Q1 2026ERNAErnexa Therapeutics-$1.95-$6.95-$5.00-$6.95N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthERNAErnexa TherapeuticsN/AN/AN/AN/AN/AGELSGelteqN/AN/AN/AN/AN/AITRMIterum TherapeuticsN/AN/AN/AN/AN/ATNFATNF PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioERNAErnexa TherapeuticsN/A2.892.89GELSGelteqN/A0.09N/AITRMIterum TherapeuticsN/A2.131.96TNFATNF PharmaceuticalsN/A0.930.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipERNAErnexa Therapeutics70.55%GELSGelteqN/AITRMIterum Therapeutics9.21%TNFATNF Pharmaceuticals9.64%Insider OwnershipCompanyInsider OwnershipERNAErnexa Therapeutics0.53%GELSGelteqN/AITRMIterum Therapeutics2.00%TNFATNF Pharmaceuticals0.45%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableERNAErnexa Therapeutics101.17 million1.16 millionNo DataGELSGelteqN/A10.71 millionN/AN/AITRMIterum Therapeutics1053.29 million52.23 millionNot OptionableTNFATNF Pharmaceuticals61.85 million1.84 millionN/AITRM, TNFA, ERNA, and GELS HeadlinesRecent News About These CompaniesTNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol “TNFA” Effective Before Market Open TodayJune 23, 2026 | businesswire.comTnf Pharmaceuticals: A Corporate Pivot Under ScrutinyFebruary 24, 2026 | newscase.comNWhy did QCLS stock surge over 60% today?December 4, 2025 | msn.comRheumatoid Arthritis Market to Surge by 2034 as Next-Generation Biologics and JAK Inhibitors Gain Traction | DelveInsightNovember 5, 2025 | finance.yahoo.comForward Therapeutics Announces First Participants Dosed in Phase 1 Healthy Volunteer Study of FT2109, a Next-Generation TNF Signaling InhibitorOctober 30, 2025 | markets.businessinsider.comQ/C Technologies (Formerly TNF Pharmaceuticals) Commences Trading on Nasdaq Under New Ticker Symbol "QCLS"September 26, 2025 | tmcnet.comTNF Pharmaceuticals changes name to Q/C TechnologiesSeptember 25, 2025 | msn.comTNF Pharmaceuticals stock soars after strategic pivot to quantum computingSeptember 25, 2025 | investing.comTNF Pharmaceuticals regains compliance with NasdaqSeptember 17, 2025 | msn.comTNF Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RequirementSeptember 17, 2025 | businesswire.comTNF Pharmaceuticals Announces Closing of $7 Million Private PlacementSeptember 4, 2025 | businesswire.comTNF Pharmaceuticals stock climbs after securing exclusive crypto computing rightsSeptember 2, 2025 | investing.comPharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency ApplicationsSeptember 2, 2025 | businesswire.comTNF Pharmaceuticals Announces Reverse Stock Split For Nasdaq Listing ComplianceAugust 29, 2025 | finance.yahoo.comTNF Pharmaceuticals announces improved financial positionAugust 20, 2025 | msn.comTNF Pharmaceuticals Strengthens Financial Position for Growth and Value CreationAugust 19, 2025 | businesswire.comTNF Pharmaceuticals Inc Ordinary Shares TNFA - MorningstarJuly 11, 2025 | morningstar.comMAkers files written objection to her Judicial Investigative admonishmentJuly 4, 2025 | wvgazettemail.comWDorothy Marillyn AkersJuly 2, 2025 | chattanoogan.comCNewly-signed running back Cam Akers has already changed his jersey numberJune 30, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWashington’s Quantum Push Puts IBM and IonQ on the ThroneBy Jeffrey Neal Johnson | June 25, 2026Cerebras Systems, Inc: The Next Rags-to-Riches AI Story?By Thomas Hughes | June 25, 2026Short Squeeze Alert—Moderna Stock Surges on New StrategyBy Chris Markoch | July 1, 20262 Quantum Stocks That Could Challenge IonQ’s LeadershipBy Nathan Reiff | July 15, 2026Meta's Internal Turmoil: Morale Nears 20-Year Low at the Wrong TimeBy Leo Miller | June 24, 2026ITRM, TNFA, ERNA, and GELS Company DescriptionsErnexa Therapeutics NASDAQ:ERNA$4.54 -0.89 (-16.39%) Closing price 04:00 PM EasternExtended Trading$4.61 +0.07 (+1.48%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Gelteq NASDAQ:GELS$0.61 +0.02 (+3.41%) Closing price 03:52 PM EasternExtended Trading$0.62 +0.01 (+0.84%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Gelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc. is based in NEW YORK.Iterum Therapeutics NASDAQ:ITRM$0.03 0.00 (0.00%) As of 07/20/2026Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.TNF Pharmaceuticals NASDAQ:TNFA$3.45 +0.01 (+0.29%) As of 07/20/2026TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3M's Redemption Arc: Can Q2 Earnings Change the Narrative? Alphabet Is Planning a New AI Chip. Here's Why It Matters Ahead of Earnings 3 Photonics Companies Making Quantum Tech Possible Confidence Is Back, But Earnings Show the Consumer Is Being Picky Industrial and Utility Giants Boost Dividends as Data Center Tailwinds Build IREN’s $2.8 Billion AI Contract Haul Changes the Stock’s Story AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 2 ETFs to Access the World's Best-Performing Stock Markets In 2026 Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
